1.A case of leukemia cutis in acute megakaryoblastic leukemia.
Jung OH ; Chang Suk KANG ; Sang In SHIM ; Sun Moo KIM
Korean Journal of Clinical Pathology 1992;12(4):467-471
No abstract available.
Leukemia*
;
Leukemia, Megakaryoblastic, Acute*
2.A Case of Acute Megakaryoblastic Leukemia.
Hye Sun JUNG ; Ha Baik LEE ; Hahng LEE ; Chong Moo PARK
Journal of the Korean Pediatric Society 1985;28(4):390-395
No abstract available.
Leukemia, Megakaryoblastic, Acute*
3.An Unusual Case of Myeloperoxidase-Positive Acute Megakaryoblastic Leukemia.
Hyeyoung LEE ; Yonggoo KIM ; Yoo Jin KIM ; Kyungja HAN
Annals of Laboratory Medicine 2015;35(4):466-468
No abstract available.
Leukemia, Megakaryoblastic, Acute*
5.A Case of Acute Megakaryoblastic Leukemia in infantwith down Syndrome.
Jang Sik MOON ; Hae Young HWANG ; Sejung SOHN ; Hak Soo LEE ; Heum Rye PARK
Journal of the Korean Pediatric Society 1990;33(10):1441-1446
No abstract available.
Down Syndrome*
;
Leukemia, Megakaryoblastic, Acute*
6.A case of acute megakaryoblastic leukemia with Down syndrome.
Sung Jin CHANG ; Sung Min SOHN ; Heung Sik KIM ; Chin Moo KANG ; Dong Seok JEON
Journal of the Korean Pediatric Society 1991;34(12):1730-1735
No abstract available.
Down Syndrome*
;
Leukemia, Megakaryoblastic, Acute*
7.A Case of Acute Megakaryoblastic Leukemia in Infant with Down's Syndrome.
Jung Soon WHANG ; Soon hee KIM ; Moon Ja KIM ; Keun LEE ; Je Geun CHI
Journal of the Korean Pediatric Society 1988;31(8):1064-1070
No abstract available.
Down Syndrome*
;
Humans
;
Infant*
;
Leukemia, Megakaryoblastic, Acute*
8.A case of acute megakaryoblastic leukemia with chloroma in infant.
Jin Seop SHIM ; Hye Kyeong NAM ; Won Suk SUH ; Sang Man SHIN ; Sang Jhoo LEE ; Won Bae KIM
Korean Journal of Hematology 1991;26(1):201-208
No abstract available.
Humans
;
Infant*
;
Leukemia, Megakaryoblastic, Acute*
;
Sarcoma, Myeloid*
9.Long-term Complete Remission in a 71-year-old Patient with AML-M7 after Low-dose Cytarabine Induction and Intermediate-dose Cytarabine Consolidation Treatment.
Ji Hyun KWON ; Ji Won KIM ; Jin Hyun PARK ; Youngil KOH ; Jee Hyun KIM ; Su Mi BANG ; Junghan SONG ; Jong Seok LEE
Korean Journal of Hematology 2009;44(4):244-248
The authors describe the case of a 71-year-old patient with acute megakaryocytic leukemia (AML-M7) who was successfully treated with low-dose cytarabine induction followed by intermediate-dose cytarabine consolidation therapy. The patient presented with infection and rapidly increasing blood blasts. The diagnosis was consistent with AML-M7 with a normal karyotype. Peripheral blood blasts decreased rapidly upon low-dose cytarabine administration, and the patient achieved complete remission after two courses of low-dose cytarabine (10 mg/m2 bid for 12 days). Consolidation therapy with intermediate-dose cytarabine (1.0 g/m2 bid on day 1, 3 and 5) was then instituted without serious complication. He remained in complete remission at the time of writing 47 month after diagnosis. In spite of multiple poor prognostic factors, this patient showed excellent treatment outcome through low-dose cytarabine induction and intermediate- dose cytarabine consolidation. It needs to be validated whether acute leukemia with a megakaryocytic morphology is exceptionally sensitive to cytarabine.
Aged
;
Cytarabine
;
Humans
;
Karyotype
;
Leukemia
;
Leukemia, Megakaryoblastic, Acute
;
Leukemia, Myeloid, Acute
;
Treatment Outcome
;
Writing
10.GATA1-positive Acute Megakaryoblastic Leukemia in a 6.9-year-old Patient with Down Syndrome: What is the Prognosis?
Joohyun PARK ; Youn Kyung LEE ; Meerim PARK ; Bo Ra SON ; Ja Young SEO ; Hee Jin KIM ; Ho Joon IM ; Yeon Jung LIM
Clinical Pediatric Hematology-Oncology 2013;20(1):66-70
We describe a very rare case of 6.9-year-old boy with Down syndrome (DS) and a prior history of transient myeloproliferative disorder. He was diagnosed with acute megakaryoblastic leukemia and found to have a novel GATA1 gene mutation, as well as a complex karyotype without recurrent acute myeloid leukemia (AML) aberrations. The patient achieved an early bone marrow response to chemotherapy. However, relapse occurred during treatment, 9 months after the initial diagnosis. Although GATA1 mutations are closely associated with DS-AML, we speculate that factors other than the presence of the GATA1 mutation can affect the overall outcome in older pediatric patients.
Bone Marrow
;
Down Syndrome
;
Humans
;
Karyotype
;
Leukemia, Megakaryoblastic, Acute
;
Leukemia, Myeloid, Acute
;
Myeloproliferative Disorders
;
Recurrence
Result Analysis
Print
Save
E-mail